Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
Cerilliant
Baxter
Medtronic
Deloitte
Chinese Patent Office
Mallinckrodt
Boehringer Ingelheim
US Army

Generated: February 17, 2018

DrugPatentWatch Database Preview

APTIVUS Drug Profile

« Back to Dashboard

Which patents cover Aptivus, and when can generic versions of Aptivus launch?

Aptivus is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are three patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-one countries.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.
Summary for APTIVUS
Drug patent expirations by year for APTIVUS
Pharmacology for APTIVUS
Drug ClassProtease Inhibitor
Mechanism of ActionHIV Protease Inhibitors

US Patents and Regulatory Information for APTIVUS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for APTIVUS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,169,181 Compounds useful to treat retroviral infections ➤ Sign Up
6,121,313 Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds ➤ Sign Up
6,531,139 Self-emulsifying formulation for lipophilic compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for APTIVUS

Supplementary Protection Certificates for APTIVUS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0047 France ➤ Sign Up PRODUCT NAME: TIPRANAVIR; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
2005008,C0758327 Lithuania ➤ Sign Up PRODUCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
C034/2005 Ireland ➤ Sign Up SPC034/2005: 20061023, EXPIRES: 20200503
00216 Netherlands ➤ Sign Up PRODUCT NAME: TIPRANAVIR, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0216 Netherlands ➤ Sign Up 300216, 20150504, EXPIRES: 20200503
0758327/01 Switzerland ➤ Sign Up FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
2005 00052 Denmark ➤ Sign Up
2005008 Lithuania ➤ Sign Up PRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
C/GB06/009 United Kingdom ➤ Sign Up PRODUCT NAME: (R-(R*,R*))-N-(3-(1-(5,6-DIHYDRO-4-HYDROXY-2-OXO-6-(2-PHENYLETHYL)-6-PROPYL-2H-PYRAN-3-YL)PROPYL)PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE OR A PHARMACEUTICAL SALT THEREOF = (TIPRANAVIR OR A PHARMACEUTICAL SALT THEREOF); REGISTERED: CH 57330 20050825; UK EU/1/05/315/001 20051025
220 Luxembourg ➤ Sign Up 91220, EXPIRES: 20200504
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Fuji
QuintilesIMS
Accenture
Farmers Insurance
Harvard Business School
Mallinckrodt
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot